B. Lynne Parshall
Board Member
Foghorn Therapeutics Inc. (FHTX)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About B. Lynne Parshall
B. Lynne Parshall is recorded as Board Member at Foghorn Therapeutics Inc. (FHTX). Ionis Pharmaceuticals Inc reported in an 8-K filed March 9, 2026 that B. Lynne Parshall retired as member of the Board of Directors. Foghorn Therapeutics Inc. reported in an 8-K filed August 17, 2022 that B. Lynne Parshall was appointed Class III Director, effective August 16, 2022.
“On March 3, 2026, B. Lynne Parshall, a member of the Board of Directors ("Board") of Ionis Pharmaceuticals, Inc. (the "Company"), and member of the Compliance Committee and Finance Committee of the Board, notified the Company that she will be retiring from the Board at the end of her current term and not seeking re-election at the Company's 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting").”
“On August 16, 2022, the Board of Directors (the "Board") of Foghorn Therapeutics Inc. (the "Company"), upon the recommendation of the Board's Nominating and Corporate Governance Committee, elected B. Lynne Parshall to the Board as a Class III Director with a term to expire at the 2023 annual meeting of stockholders.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2022-08-16–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Foghorn Therapeutics Inc.
Other people whose current roles at this company are on record from its filings.
- Adrian Gottschalk CEO, Board Member
- Jeff Sacher CFO
- Kristian F. Humer CFO, Chief Accounting Officer
- Ryan D. Maynard CFO
- Ryan Maynard CFO
- Stephen J. DiPalma CFO
- Steven Bellon CTO
- Ian F. Smith Board Member
- Neil J. Gallagher, M.D., Ph.D. Board Member
- Stuart Duty Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.